Pramipexol

( DrugBank: Pramipexol / KEGG DRUG: Pramipexole )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	129

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

trials per page:

Showing 1 to 10 of 129 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000039050	2020-10-30	2020-10-14	Efficacy of levodopa/carbidopa/entacapone in the replacement of Levodopa /dopa decarboxylase inhibit ...	Efficacy of levodopa/carbidopa/entacapone in the replacement of Levodopa /dopa decarboxylase inhibit ...	Parkinson's Disease	Group 1:adding pramipexole;Group 2:adding LCE;	The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)	NULL	Pending	30	80	Both	Group 1:175;Group 2:175;	Phase 4	China
2	ChiCTR2000037624	2020-10-01	2020-08-29	Clinical efficacy of dopamine agonist Pramipexolin the treatment of cognitive impairment in PATIENTS ...	Clinical efficacy of dopamine agonist Pramipexolin the treatment of cognitive impairment in PATIENTS ...	Parkinson's disease	experimental group:Pramipexol + dopa hydrazine combination therapy;control group: dopa hydrazine;	Shanghai General Hospital	NULL	Recruiting	18	85	Both	experimental group:50;control group:50;		China
3	ChiCTR2000035564	2020-08-17	2020-08-13	Pharmacokinetics and Bioequivalence study of Pramipexole Extended-Release Tablets in Healthy Chinese ...	Pharmacokinetics and Bioequivalence study of Pramipexole Extended-Release Tablets in Healthy Chinese ...	Parkinson’s disease	fasting administration group-TR:phase I: Pramipexole Extended-Release Tablets; phase II: Reference p ...	West China Hospital of Sichuan University	NULL	Recruiting	18	65	Both	fasting administration group-TR:28;fasting administration group-RT:28;high-fat postprandial administration group-TR:28;high-fat postprandial administration group-RT:28;	Phase 1	China
4	NCT04275492 (ClinicalTrials.gov)	July 24, 2020	18/11/2019	Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets	Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets	Parkinson's Disease	Drug: Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole h ...	First Affiliated Hospital of Zhejiang University	Hongguan biological pharmaceutical co.	Recruiting	18 Years	45 Years	All	60	N/A	China
5	NCT04249544 (ClinicalTrials.gov)	December 3, 2019	28/1/2020	Social Decision Making in Parkinson's Disease	Cognitive and Neural Mechanisms of Impaired Social Decision-Making in Parkinson's Patients Taking Do ...	Parkinson Disease	Drug: Pramipexole;Drug: Placebo	Vanderbilt University Medical Center	United States Department of Defense	Recruiting	45 Years	80 Years	All	60	Phase 1	United States
6	ChiCTR1900021708	2019-07-01	2019-03-05	Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients bas ...	Study for the brain network mechanism of pramipexole in the treatment of tremor-type PD patients bas ...	Parkinson's Disease	Healthy control group:No;tremor-dominant phenotype PD patients group:pramipexole;	Department of Neurology, Brain Hospital Affiliated to Nanjing Medical University	NULL	Pending	50	70	Both	Healthy control group:80;tremor-dominant phenotype PD patients group:80;		China
7	ChiCTR1900022534	2019-06-01	2019-04-15	Efficacy of entacapone and pramipexole for non-motor symptoms of Parkinson’s disease: a prospective ...	Efficacy of entacapone and pramipexole for non-motor symptoms of Parkinson’s disease: a prospective ...	non-motor symptoms of Parkinson’s disease	entacapone group:Patients in the entacapone group will be administered entacapone (Novartis; import ...	Geriatric Hospital of Hainan	NULL	Pending	40	75	Both	entacapone group:194;pramipexole group:194;	N/A	China
8	NCT03845387 (ClinicalTrials.gov)	February 26, 2019	15/2/2019	A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.	A Phase II Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.	Parkinson Disease	Drug: KDT-3594;Drug: Pramipexole	Kissei Pharmaceutical Co., Ltd.	NULL	Completed	20 Years	79 Years	All	74	Phase 2	Japan
9	ChiCTR1800019942	2018-12-31	2018-12-09	A Multicenter Randomized Controlled Trial for Effect of Zishen Pingchan Granules Combined with Prami ...	A Multicenter Randomized Controlled Trial for Effect of Zishen Pingchan Granules Combined with Prami ...	Parkinson’s Disease	Experimental group:Zishen Pingchan Granules combined with Pramipexole;Control group:Zishen Pingchan ...	The Affiliated Brain Hospital of Nanjing Medical University( Nanjing Brain Hospital)	NULL	Pending	30	85	Both	Experimental group:150;Control group:150;		China
10	NCT03521635 (ClinicalTrials.gov)	July 3, 2018	11/4/2018	The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrn ...	A Two- Stage Multicenter, Open-label, Randomized, Active Controlled Parallel Group Study Comparing t ...	Parkinson Disease	Drug: Pramipexole SR;Drug: Pramipexole IR	Boehringer Ingelheim	NULL	Completed	30 Years	N/A	All	98	Phase 4	China

First Previous1 2 3 4 5…13Next Last